West German Study Group

Aalen, Baden-Wurttemberg

OncologyPhase III

What changed

Phase II trial registered: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

5w agoTrial registeredJun 9, 2026Source filing (opens the source filing in a new tab)

Momentum

96no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

408 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE3 registered
Apr 29, 2026
Breast Cancer, HR+/HER2- Breast Cancer · RECRUITING · sponsor: West German Study Group · Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
ClinicalTrials.gov · NCT07242352 (opens the source filing in a new tab)
Trial
PHASE2 registered
Feb 5, 2024
HER2-positive Early Breast Cancer · RECRUITING · sponsor: West German Study Group · NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
ClinicalTrials.gov · NCT05704829 (opens the source filing in a new tab)
Trial
Study registered
Dec 7, 2022
Female Breast Cancer · RECRUITING · sponsor: West German Study Group · PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
ClinicalTrials.gov · NCT05792150 (opens the source filing in a new tab)
Trial
PHASE3 registered
Sep 2, 2020
Breast Cancer Female · ACTIVE_NOT_RECRUITING · sponsor: West German Study Group · Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
ClinicalTrials.gov · NCT04565054 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jul 2, 2019
Breast Cancer Female · ACTIVE_NOT_RECRUITING · sponsor: West German Study Group · Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
ClinicalTrials.gov · NCT04055493 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 1, 2014
Breast Cancer · COMPLETED · sponsor: West German Study Group · A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol
ClinicalTrials.gov · NCT01817452 (opens the source filing in a new tab)
Trial
PHASE2 registered
Nov 1, 2012
Breast Cancer · COMPLETED · sponsor: West German Study Group · A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
ClinicalTrials.gov · NCT01745965 (opens the source filing in a new tab)
Trial
PHASE2/PHASE3 registered
May 1, 2012
Breast Cancer · COMPLETED · sponsor: West German Study Group · Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
ClinicalTrials.gov · NCT01781338 (opens the source filing in a new tab)
Trial
PHASE2/PHASE3 registered
May 1, 2012
Breast Cancer · COMPLETED · sponsor: West German Study Group · ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
ClinicalTrials.gov · NCT01779206 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.97name similarity 100% · semantic similarity 80% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
new_entity links the trial record at 0.53name similarity 100% · same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
5w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
5w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
2mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
5mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
5mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
8mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase II trial registered: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Feb 2025Trial completedSource (opens the source filing in a new tab)
Phase III trial registered: Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Feb 2025Trial completedSource (opens the source filing in a new tab)
Phase II trial registered: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol
Feb 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

PHASE3 registered

PHASE2 registered

Study registered

PHASE3 registered

PHASE3 registered

PHASE2 registered

PHASE2 registered

PHASE2/PHASE3 registered

PHASE2/PHASE3 registered